Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Radiotherapy of unresectable pancreatic carcinoma: a six year experience with 104 patients. [/sup 125/I; Betatron]

Journal Article · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)
From 1974 to 1980, 104 patients with unresectable carcinoma of the pancreas were seen in the Department of Radiation Therapy at Thomas Jefferson University Hospital. Sixty-six patients were accepted for definitive therapy. Of these, 48 patients received precision high dose radiotherapy to a dose of 6800 rad on the 45 MeV Betatron, using either photons alone or mixed photon and high energy electron beams. Eighty-nine percent of the patients completed treatment as per the protocol. Relief of symptoms was obtained in 65% of patients. Median survival was 10 months. In spite of the high doses employed, 67% of the patients had evidence of recurrent tumor in the treatment volume at the time of death. In view of the high incidence of local failure with precision high dose therapy alone, a protocol using Iodine-125 implantation to supplement the external beam therapy was developed in 1978. Since then, 18 patients with disease confined to the region of the pancreas were treated with the combination of Iodine-125 implantation and precision high dose therapy. Eighty-five percent of the patients completed treatment. Follow-up ranges from eight to 22 months. None of the patients completing the treatment protocol have developed local recurrence of tumor. These results are presented together with details of the treatment technique, normal tissue reactions and implications for future approaches to the treatment of localized unresectable cancer of the pancreas.
OSTI ID:
6854042
Journal Information:
Int. J. Radiat. Oncol., Biol. Phys.; (United States), Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Vol. 7:12; ISSN IOBPD
Country of Publication:
United States
Language:
English